Table 1 Comprehensive list of PD-L1 inhibitors along with FDA-approved disease treatment, clinical trials, and primary endpoints

Atezolizumab (MPDL3280A), Roche Genentech

NSCLC

Atezolizumab vs docetaxel

OS, 15.7 months vs 10.3 months

[42]

NSq NSCLC

Atezolizumab, carboplatin, paclitaxel, and bevacizumab vs atezolizumab; carboplatin and paclitaxel vs carboplatin, paclitaxel, and bevacizumab

OS 19.2 months (4 drugs) vs 14.7 months (3 drugs)

[43]

UC

Atezolizumab vs chemotherapy

OS 11.1 months vs 10.6 months

[37, 38]

ES-SCLC

Atezolizumab, carboplatin, and etoposide vs carboplatin and etoposide

PFS 5.2 months vs 4.3 months; OS 12.3 months vs 10.3 months

[44]

TNBC

Atezolizumab plus nab-paclitaxel vs nab-paclitaxel

PFS 7.5 months vs 5.0 months; OS 25.0 months vs 15.5 months

[45]

Durvalumab (MEDI4736), AstraZeneca

UC

Durvalumab

ORR 17.8%

[59]

Unresectable stage III NSCLC

Durvalumab vs placebo

PFS 16.8 months vs 5.6 months

[60]

Avelumab (MSB0010718C), Merck and Pfizer

MCC

Avelumab

ORR 33% (11% complete and 22% partial)

[69]

UC

Avelumab

ORR 16.1% at least 6 months

[70, 71]

RCC

Avelumab plus axitinib vs sunitinib

PFS 13.8 months vs 8.4 months

[79]

Envafolimab (KN035), Alphamab Oncology

N/A

N/A

[80, 81]

BMS-936559, Bristol-Myers Squibb

N/A

N/A

[82]

CK-301,Checkpoint Therapeutics

N/A

N/A

[83]

CS-1001, CStone Pharmaceuticals

N/A

N/A

[84]

SHR-1316 (HTI-1088), Hengrui Therapeutics

N/A

N/A

[85]

BGB-A333, BeiGene

N/A

N/A

[86]